Access to healthcare
Healthy communities are the backbone of strong, sustainable societies. But there are still millions of people without access to basic healthcare. We want to help change this. So we are harnessing our scientific expertise, our partnerships and our global reach to develop and make products for people who need them, wherever they live.
Vaccines Access Initiative
The objective of this initiative is to provide complementary access points for adult vaccines that are not on the Extended Programme for Immunisation (EPI) list.
Open Lab for non-communicable disease in Africa
In 2015, GSK started an initiative to build the world’s first R&D Open Lab for non-communicable diseases in Africa.
The Africa NCD Open Lab will see GSK scientists collaborate with research and scientific centres across Africa from its hub in Stevenage in the UK. They will conduct research to increase understanding of NCDs in Africa, helping to inform prevention and treatment strategies.
The Open Lab will directly support the training and education of African scientific researchers who will participate in a portfolio of projects, building local expertise and creating a new generation of African NCD experts while instilling a deep vein of ‘African thinking’ within GSK’s own R&D organisation.
A research fund has been established by GSK to support Africa-based researchers working on projects at the NCD Open Lab. The GSK Nigeria medical team drove the participation of HCPs for the research through awareness programmes and by reviewing various proposals submitted from all over Africa. At the end of the exercise, one of the entries from Nigeria was awarded the grant.
The Access to Medicines Index
Recognizing our achievements in bringing access to healthcare globally, we have consistently ranked top in the Access to Medicines (ATM) Index since it began in 2008. The Index, published every two years, gives an independent assessment of pharmaceutical companies’ efforts to improve access. Our recent ranking as top of the 2014 Index reflects our long-term commitment to bringing access to healthcare across the world.
In Nigeria, it is our ambition to transform healthcare access in Nigeria by ensuring that 4 out of every 5 Nigerians have access to and use a GSK medicine regardless of where they are located or their ability to pay by the year 2020. This vision, called the Africa 2020 agenda, is particularly important because Sub-Saharan Africa, including Nigeria has one of the lowest life expectancies in the world partly because of inadequate access to quality medicines and vaccines. The Africa 2020 agenda seeks to extend medicine access to the bottom of the pyramid, and improve the quality of millions of lives more in the process.
Better access to medicines and vaccines
We want our medicines and vaccines to be accessible to everyone who needs them, no matter where they live or how much they can afford. Flexible pricing of our medicines and vaccines, based on a country’s wealth and ability to pay, generates value for patients and society more widely.
There are no easy solutions to providing sustainable healthcare in developing countries. Many people do not have enough food or access to clean water, let alone access to hospitals or clinics that provide professional help and treatments.
Patient access programme in Nigeria
Access to quality medicines has been identified as one of the greatest challenges facing Africa. According to the WHO, many of the most neglected people in terms of healthcare live in the poorest countries often in Sub-Saharan Africa and in the rural areas.
In Nigeria over 70% of the population live in the semi urban and rural areas, where affordability and access to quality medicines is a major challenge. GlaxoSmithKline has created its patient access program with the aim of providing appropriate and affordable medications for common diseases and conditions like asthma, malaria, pain and fever, worm infection, common infections etc. Our dedicated patient access team aims to provide access of GSK medicines to far reaching places (Sub-urban and rural) communities and patients who because of their peculiar geographical location and Socio-economic status do not necessarily have access to these medicines and healthcare. It is expected that by 2020, 4 in every 5 Nigerians will have access to GSK brands.
Working with others
By working in partnership with non-governmental organizations (NGOs), governments, academic institutions and other companies, we can achieve more for patients than we can alone.
We are a long-standing partner of GAVI, which funds immunisation programmes for some of the world’s poorest countries. GAVI-eligible countries always get our lowest prices, which can be as little as one-tenth of those for developed nations. GAVI supports countries with a GNI per head of less than $1,570. As countries develop and exceed this GNI threshold, they ‘graduate’ from GAVI support. We have committed to freeze vaccine prices for graduating countries for ten years to help them maintain their commitment to immunisation during this transition. We have committed to provide GAVI with more than 850 million vaccine doses at reduced prices to help protect 300 million children in the developing world by 2024.
But we also want to help improve health beyond our products by acting as a catalyst for change. So we reinvest 20% of our profits from least developed countries back into strengthening their health systems – primarily through training health workers with three major NGOs: Amref Health Africa, CARE International and Save the Children. Together, we have so far trained 40,000 frontline health workers in least developed countries and reached more than 11 million people.
In 2013 we formed an innovative five-year partnership with Save the Children to help save 1 million children’s lives. By combining our expertise, resources and capabilities, we will help bring much-needed medicines and vaccines to some of the world’s poorest children, train thousands of healthcare workers, and develop child-friendly medicines. In our maternal and neonatal R&D unit, scientists are developing a gel form of a GSK mouthwash ingredient to help prevent sepsis in newborn babies.